EVENTS | VIEW CALENDAR
Ambry Genetics launches Fluidigm-based genomic research services
ALISO VIEJO, Calif.—Ambry Genetics, a global leader in clinical diagnostics and genomic services, announced last month the launch of Fluidigm BioMark HD and Access Array System-based genomic research services. These services provide gene expression, SNP genotyping and sample preparation for targeted sequencing using next-generation sequencers, and are focused on the genomics research market.
The BioMark HD System is one of the most advanced genomic analysis instruments on the market today. It provides the sensitivity and throughput needed to study gene expression profiles down to the single-cell level, as well as high throughput SNP genotyping and digital PCR for copy number variation and rare mutation detection. The Access Array System enables high-throughput, target-enrichment for all of the major next-generation sequencing instruments and allows users to enrich multiple unique targets (such as exons) from a large number of samples, all at one time and at low cost.
Ambry Genetics offers a wide variety of genomic services that will be enhanced by the addition of Fluidigm platforms. Separately, from a regulatory standpoint Ambry can offer its other services within a CLIA setting and deliver the highest quality of data, while handling large volumes of samples with automation in place.
"For months, many of our genomics customers have been clamoring for Fluidigm technologies from single-cell gene expression to sample prep for targeted resequencing. We are ready to unleash the power of Fluidigm platforms and are anxious to offer our customers these enhanced capabilities," said Charles Dunlop, CEO of Ambry Genetics, in a statement. "Over the past decade, Ambry Genetics has developed one of the best reputations in the genomics industry, and a big reason is our many technology platforms and our technical abilities to apply them. Having the Fluidigm technology in house is a major step forward for us, and will continue to solidify Ambry's reputation as a leader in this space."
"Ambry Genetics has a first-class reputation as an adopter of leading technologies," added Gajus Worthington, president and CEO of Fluidigm. "We at Fluidigm are thrilled that our products will be part of Ambry's portfolio of services, and we are excited about the prospect of working closely together. With the combined expertise, customer focus, and technological prowess of Fluidigm and Ambry, we are confident we will deliver a new level of value to Ambry's customers."